Pharmaceutical Executive® unveils 21st annual Pharma 50

“With the end of the COVID-19 pandemic in sight, the Pharmaceutical executive® The Pharma 50 list shows the top sellers who have played a role in addressing the public health crisis facing the industry, ”said Mike Hennessy Jr., President and CEO of MJH Life Sciences ™, parent company of Pharmaceutical executive®. “Although the Pharma 50 has provided an intuitive overview of the industry’s top 50 biopharmaceutical companies for more than 20 years, the companies have recognized that this year faces an even greater challenge due to the pandemic. research, awareness and education, they have played at the highest level. “

In addition to paying particular attention to current connected trends, Pharmaceutical executive® based its ranking of the world’s top 50 biopharmacy leaders on the companies’ annual prescription drug sales in 2020. Data for the list is provided in partnership with life science marketing intelligence firm Evaluate Ltd. top-selling products and their total research and development (R&D) spending.

Roche, which generated $ 47.5 billion in prescription drug sales, ranked first for the second year in a row. Avastin remains the company’s best-selling drug with $ 5.3 billion in 2020 sales. Roche, which was also the first investor in biopharma R&D after investing $ 11.3 billion, has 19 compounds in Phase III clinical trials or submitted for approval.

Novartis ranks second in prescription drug sales, ranking second for the second year in a row and up 2.4% to $ 47.2 billion of the previous year. To complete the top 5 of the Pharma 50, AbbVie, which moved from eighth place in 2020 to third; Johnson & Johnson with 7.7% growth in prescription drug revenue, pushing it up two places to fourth; and Bristol Myers Squibb, which reclaims fifth place with a 3% increase in sales of prescription drugs to $ 41.9 billion.

To view the full list of Pharma 50s, click here.

About Pharmaceutical executive®
Pharmaceutical Director® is a multimedia platform that offers news, opinions, analysis, features and executive profiles. The magazine and its website serve as a forum for industry leaders to exchange opinions, experiences and ideas on innovative business and marketing ideas, strategies and tactics. Pharmaceutical executive® is a trademark of MJH Life Sciences™, the largest private, independent, full-service medical media company in North America, dedicated to disseminating reliable healthcare information across multiple channels.

Pharmaceutical executive® Media contact
Alexandra Ventura, 609-716-7777
[email protected]

SOURCE Pharmaceutical Executive®

Source link

About Catherine Sherrill

Check Also

Do analysts agree on Kala Pharmaceuticals Inc (KALA) target price on Monday?

Wall Street is positive on Kala Pharmaceuticals Inc (KALA). On average, analysts give KALA a …

Leave a Reply

Your email address will not be published. Required fields are marked *